EU regulator to unveil Astrazeneca vax assessment

The EMA's safety committee has been making a detailed evaluation of a small number of cases concerning blood clots occurring in recipients of the vaccine, reports dpa news agency. 

The Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is to issue any necessary recommendations for further action after its meeting on Thursday. 

The European nations that has halted the usage of the vaccine are France Germany, Italy, Spain, Slovenia, Cyprus, Portugal, Austria, Bulgaria, Denmark, Romania, Estonia, Lithuania, Luxembourg, Latvia, the Netherlands, as well as non-EU countries of Norway and Iceland. 

Many said they were waiting for guidance from the EMA. 

The EMA said it was looking at available data related to all thromboembolic events reported after vaccination, including additional data provided by national health agencies. 

"Rapid and thorough analysis of the available data and clinical circumstances surrounding specific cases is continuing, to determine whether the vaccine might have contributed or if events are likely to have been due to other causes," the EMA said. 

Both the EMA and the World Health Organization (WHO) recommended continuing inoculation with AstraZeneca's vaccine until further notice, noting its benefits outweighed the risks of Covid-19.